科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ Antimicrobial Agents and Chemotherapy2026-02-12· Selection (genetic algorithm)

<i>In vivo</i> selection of CMY-219 conferring resistance to ceftazidime-avibactam in an OXA-484-producing <i>E. coli</i> ST410

Agnès B. Jousset, Delphine Girlich, Saoussen Oueslati, Aurélien Birer, Anne Delaval, Caroline Guyot, Inès Rezzoug, Cécile Emeraud, Thierry Naas, Rémy A. Bonnin, L Dortet

原始摘要(英文原文)· Original abstract
ABSTRACT Resistance to ceftazidime-avibactam (CAZ-AVI) is a growing problem. This study describes the selection of CMY-219, a CMY-42 variant (G156D), conferring resistance to CAZ-AVI in an OXA-484-producing Escherichia coli ST410 after treatment. It raises concern about the risk of selection of CMY variants under CAZ-AVI exposure in ST410 and related clones, which commonly carry CMY-42, are prone to carbapenemase acquisition, and harbor modified PBP3.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

<i>In vivo</i> selection of CMY-219 conferring resistance to ceftazidime-avibactam in an OXA-484-producing <i>E. coli</i> ST410 — 科研速览 Science Skim